Remove use-case go-to-market
article thumbnail

STAT+: Explaining Change Healthcare and the gravity of its cyberattack

STAT

Using terms like “clearinghouse” and “electronic data interchange” are quick ways to lose an audience. He didn’t get into health economics to study the payment plumbing system, but understanding basic concepts about companies like Change Healthcare can illuminate the gravity of what is going on now.

Hospitals 334
article thumbnail

STAT+: Despite court ruling, FDA will continue with its approach to approving orphan drug exclusivity

STAT

In an unexpected move, the Food and Drug Administration will continue to apply exclusive marketing rights for so-called orphan drugs under its existing regulations, rather than take a broader approach suggested by a federal court in a highly controversial case involving one such medicine.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: FDA proposes changes to key approval pathway for medical devices, five years after promising

STAT

Five years after promising to fix a flawed regulatory pathway widely used by medical device manufacturers, the Food and Drug Administration has issued new guidelines to improve its so-called 510(k) program that has long been lambasted for letting risky devices fall through the cracks. Continue to STAT+ to read the full story…

331
331
article thumbnail

STAT+: Drastic changes should bring profitability, startup health insurers say

STAT

Startup insurers Oscar Health, Bright Health, and Clover Health have hemorrhaged money since going public within the past two years. All three used their stage time at the J.P. Continue to STAT+ to read the full story…

197
197
article thumbnail

STAT+: Pharmalittle: EU fines Illumina $475M for closing Grail deal; life-threatening lead poisoning antidote in short supply

STAT

The drug, named dimercaprol, has been a go-to treatment for years for the worst cases of lead poisoning, but doctors have had to scrounge for dwindling doses since the sole manufacturer for the U.S. Another antidote — edetate calcium disodium, or EDTA, often used in tandem with dimercaprol — is also in short supply.

Hospitals 225
article thumbnail

Taking the right forecasting approach for rare diseases

pharmaphorum

There are clearly challenges to developing a drug targeting a rare disease, due to the small and often undiagnosed populations, and these challenges are also present when developing an accurate forecast of their market potential. For a rare disease, an epidemiological approach is the right way to go. Data and market insights.

Immunity 121
article thumbnail

Omnichannel Benchmarking: a new era of HCP engagement

pharmaphorum

This is particularly evident in marketing. This estimation could then be used to determine audience engagement and interaction success rates. Instead, companies are increasingly turning to omnichannel marketing to bridge gaps in communication created by the pandemic. Redefining HCP engagement monitoring.

Hospitals 116